Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1525-1531

  Poland, Gregory A ^a,b   Jacobson, Robert M ^a,b   Colbourne, S Ann ^c   Thampy, Aruna M ^c   Lipsky, James J ^a,b   Wollan, Peter C ^b   Roberts, Peter ^c   Jacobsen, Steven J ^a,b  

^a Mayo Vaccine Research Group   (United States)

^b MAYO CLINIC   (United States)

^c Grenfell Regional Health Services   (Canada)

Author keywords

Immunogenicity; Innu; Inuit; Measles antibody; Measles vaccine; Seroprevalence

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CANADA; FEMALE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; PRIORITY JOURNAL; SCHOOL CHILD; SEROPREVALENCE; TREATMENT FAILURE;

ADOLESCENT; ANTIBODIES, VIRAL; ASIAN CONTINENTAL ANCESTRY GROUP; CANADA; CHILD; CHILD, PRESCHOOL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOENZYME TECHNIQUES; MALE; MEASLES VACCINE; MEASLES VIRUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 0033577343     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00362-4     Document Type: Article

References (44)

1. Centers for Disease Control and Prevention Measles - United States, 1990. MMWR. 40:1991;369-372.
2. Centers for Disease Control and Prevention Measles prevention: Recommendations of the immunization practices advisory committee (ACIP). MMWR. 38:1989;11-14.
3. Centers for Disease Control and Prevention. Measles - United States, 1989 and first 20 weeks 1990. MMWR 1990;39:353-355,361-363.
4. Barkin R.M. Measles mortality: A retrospective look at the vaccine era. Am J Epidemiol. 102:1975;341-349.
5. Poland G.A., Jacobson R.M. Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons. Arch Intern Med. 154:1994;1815-1820.
6. Assaff D., Goel V., Pasut G. Measles in Ontario - Overview of 1989 cases. Canada Diseases Weekly Report. 15:1989;148-150.
7. Varughese P.V., Carter A.O., Ellis E. Measles in Canada - 1989. Canada Diseases Weekly Report. 16(1):1990;6.
8. Anon. Statement on recommended use of measles vaccine in Canada. Canadian Diseases Weekly Report 1990;15:7-10.
9. Anon. Guidelines for measles control in Canada. Can. Med. Assoc. J. 1991;144:997-1000.
10. Siber G.R., Santosham M., Reid G.R.et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med. 323:1990;1387-1392.
11. The Alaska H. Influenzae Vaccine Study Group, Ward J., Brenneman G., Letson G.W., Heyward W.L. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med. 323:1990;1393-1401.
12. Santosham M., Wolff M., Reid R.et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 324:1991;1767-1772.
13. Pedersen I.R., Mordhorst C.H., Ewald T., von Magnus H. Long-term antibody response after measles vaccination in an isolated artic society in Greenland. Vaccine. 4:1986;173-178.
14. Pedersen I.R., Mordhorst C.H., Glikmann G., von Magnus H. Subclinical measles infection in vaccinated seropositive individuals in arctic Greenland. Vaccine. 7:1989;345-348.
15. Boteler W.L., Luipersbeck P.M., Fuccillo D.A., O'Beirne A.J. Enzyme-linked immunosorbent assay for detection of measles antibody. J Clin Microbiol. 17:1983;814-818.
16. Canadian Immunization Guide. Ottawa, Canada: Canadian Centers of Disease Control, 1990.
17. Carson M, Krezoek M, Spady D et al. Success of measles vaccination in infants depends on maternal immunization history. Canadian Public Health Association 2nd National Conference on Immunization 1992, Abstracts: M.13 (abstract).
18. Johnson C.E., Nalin D.R., Chui L.W., Whitwell J., Marusyk R.G., Kumar M.L. Measles vaccine immunogenicity in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics. 93:1994;939-943.
19. Jacobson RM, Poland GA, Colbourne SA, Jacobsen SJ, Lipsky JJ, Wollan PC. The effect of maternal measles antibody status upon measles vaccine response. Abstracts of the 35th ICAAC 1995, 184-#H25 (abstract).
20. Hayney M.S., Poland G.A., Dimanlig P., Schaid D.J., Jacobson R.M., Lipsky J.J. Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine. 15:1997;3-6.
21. *13 allele on measles vaccine response. J Invest Med. 44:1996;261-263.
22. Poland GA, Hayney MS, Jacobson RM et al. The association between measles vaccine-induced antibody response and HLA-DQA1 alleles. In: Brown F, Burton D, Doherty P, Mekalanos J, Norrby E, editors. Vaccines 97: molecular approaches to the control of infectious diseases. Plainview, NY: Cold Spring Harbor Laboratory Press, 1997. p. 229-233.
23. Ward J. Commentary: Results of efficacy trials in Alaska and Finland of Haemophilus influenzae type b conjugate vaccine. Pediatrics. 85:1990;667-667.
24. Wainwright RB, Letson GW, Chiu C-Y, Bulkow LR, Burkart K, Ward JI. Immunogenicity of three Haemophilus influenzae type B HIB conjugate vaccines in Alaska native infants. Pediatr. Res. 1990, 185A (abstract).
25. Centers for Disease Control and Prevention. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the immunization practices advisory committee (ACIP). MMWR 1991;40:1-6.
26. Tan B, Pless R, Duclos P. Serological survey prior to measles outbreak in Pangnirtung, Northwest Territories. 2nd National Canadian Public Health Association Conference on Immunization 1992, M.2 (abstract).
27. Chen R.T., Markowitz L.E., Albrecht P.et al. Measles antibody: Reevaluation of protective titers. J Infect Dis. 162:1990;1036-1042.
28. King J.C. Jr., Lichenstein R., Feigelman S., Luna C., Permutt T.J., Patel J. Measles, mumps, and rubella antibodies in vaccinated Baltimore children. Am J Dis Child. 147:1993;558-560.
29. Struewing J.P., Hyams K.C., Tueller J.E., Gray G.C. The risk of measles, mumps, and varicella among young adults: A serosurvey of US Navy and Marine Corps recruits. Am J Public Health. 83:1993;1717-1720.
30. Smoak B.L., Novakoski W.L., Mason C.J., Erickson R.L. Evidence for a recent decrease in measles susceptibility among young American adults. J Infect Dis. 170:1994;216-219.
31. Neumann P.W., Weber J.M., Jessamine A.G., O'Shaughnessy M.V. Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test vs neutralization test for determination of immune status. J Clin Microbiol. 22:1985;296-298.
32. Kelley P.W., Petruccelli B.P., Stehr-Green P., Erickson R.L., Mason C.J. The susceptibility of young adult Americans to vaccine-preventable infections. A national serosurvey of US Army recruits. JAMA. 266:1991;2724-2729.
33. Kacica M.A., Venezia R.A., Miller J., Hughes P.A., Lepow M.L. Measles antibodies in women and infants in the vaccine era. J Med Virol. 45:1995;227-229.
34. Ammari L.K., Bell L.M., Hodinka R.L. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect Control Hosp Epidemiol. 14:1993;81-86.
35. Matson D.O., Byington C., Canfield M., Albrecht P., Feigin R.D. Investigation of a measles outbreak in a fully vaccinated school population including serum studies before and after revaccination. Pediatr Infect Dis J. 12:1993;292-299.
36. Anon. Grenfell clinical quarterly/Labrador profile. Grenfell Clin. Quart. 1990;6:1-32.
37. McAleer W.J., Markus H.Z., McLean A.A., Buynak E.B., Hilleman M.R. Stability on storage at various temperatures of live measles, mumps and rubella virus vaccines in new stabilizer. J Biol Stand. 8:1980;281-287.
38. Markowitz LE, Katz ML. Measles vaccine. In: Plotkin SA, Mortimer EA Jr, editors. Vaccines. 2nd ed. Philadelphia, PA: W.B. Saunders Company, 1994. p. 229-276.
39. Mann G.F., Allison L.M.C., Lloyd J.S., Tam P., Zuckerman A.J., Perkins F.T. Stability of further-attenuated measles vaccines. Rev Infect Dis. 5:1983;482-486.
40. Markowitz L.E., Orenstein W.A. Measles vaccines. Pediatr Clin North Am. 37:1990;603-625.
41. Markowitz L.E., Albrecht P., Rhodes P.et al. Changing levels of measles antibody titers in women and children in the United States: Impact on response to vaccination. Pediatrics. 97:1996;53-58.
42. Poland G.A. Variability in immune response to pathogens: using measles vaccine to probe immunogenetic determinants of response. Am J Hum Genet. 62:1998;215-220.
43. Poland G.A., Jacobson R.M. The genetic basis for variation in antibody response to vaccines. Curr Opin Pediatr. 10:1998;208-215.
44. Poland GA, Jacobson RM, Schaid DJ, Moore SB, Jacobsen SJ. Class I HLA alleles and measles vaccine-induced antibody levels: evidence of a significant association. Vaccine 1998;16:1869-1871.